01:01 , May 7, 2019 |  BC Innovations  |  Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
23:41 , May 1, 2019 |  BC Innovations  |  Translation in Brief

White matter matters in Alzheimer’s

An MIT team has identified Alzheimer’s disease-associated changes in gene expression that vary based on cell type, including myelin-related genes, suggesting new pathways that can be explored to treat the disease. Described in a Nature...
21:48 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

DISEASE CATEGORY: Autoimmune disease; neurology INDICATION: Multiple sclerosis (MS); neurology Cell culture and mouse studies suggest Conbriza bazedoxifene could help treat MS and other demyelinating diseases. In oligodendrocyte precursor cells (OPCs) derived from a human...
12:20 , Mar 26, 2019 |  BC Innovations  |  Distillery Therapeutics

The short-chain fatty acid pentanoate for MS

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis Cell culture and mouse studies suggest the short-chain fatty acid pentanoate could help treat MS. In primary mouse T helper type 17 (Th17) cells pentanoate increased expression of...
01:49 , Mar 22, 2019 |  BC Innovations  |  Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
01:15 , Jan 25, 2019 |  BC Week In Review  |  Clinical News

Asterias' oligodendrocyte progenitor cell therapy improves motor function in SCI patients at 12 months

Asterias Biotherapeutics Inc. (NYSE-A:AST) reported 12-month data from the Phase I/IIa SCiStar trial to treat cervical spinal cord injury (SCI) showing that 21 of 22 patients (95%) who received 10 or 20 million cells of...
00:56 , Jan 25, 2019 |  BC Innovations  |  Product R&D

Rubius turns immunotherapy red

As it gets ready to bring the first engineered red blood cell therapy into the clinic, Rubius Therapeutics Inc. is working up the next generation of RBC therapies to mimic immune cell interactions. The company...
00:00 , Dec 12, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Patient sample and mouse studies suggest depleting microglia with CSF1R inhibitors could help treat chemotherapy-induced neurological dysfunction. In postmortem frontal lobe tissue samples from pediatric and young adult patients treated with methotrexate and...
17:40 , Dec 11, 2018 |  BC Innovations  |  Translation in Brief

Diseased oligodendrocytes

A Karolinska Institute team has identified subsets of oligodendrocyte lineage cells that may trigger T cell immunity in multiple sclerosis and proposed the cells as new disease targets. The findings suggest the myelin-producing cells are...
17:33 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Neurology Mouse studies suggest antagonizing the muscarinic receptor CHRM1 could help treat white matter injury. In a mouse model of neonatal chronic hypoxia-induced white matter injury, CHRM1 knockout in oligodendrocyte precursor cells increased axon...